TRAW · Insider Trading
Traws Pharma, Inc. Common Stock
Every open-market purchase and sale reported by TRAW officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-16 | Charles David Pauza | Chief Science Officer Virology | A | +97,000 deriv. | — |
| 2026-07-15 | Werner Cautreels | Director | A | +14,150 deriv. | — |
| 2026-07-15 | Nikolay Savchuk | Chief Operating Officer | A | +93,000 deriv. | — |
| 2026-07-14 | Charles Nolan Parker | Chief Financial Officer | A | +90,000 deriv. | — |
| 2026-07-14 | Robert Redfield | Chief Medical Officer | A | +84,000 deriv. | — |
| 2026-07-14 | Mary Teresa Shoemaker | Director | A | +14,150 deriv. | — |
| 2026-07-14 | John Harold Leaman | Director | A | +14,150 deriv. | — |
| 2026-07-14 | Iain D. Dukes | Chief Executive Officer | A | +274,000 deriv. | — |
| 2026-07-14 | Jack E Stover | Director | A | +14,150 deriv. | — |
| 2026-07-14 | Trafford Clarke | Director | A | +14,150 deriv. | — |
| 2026-04-28 | OrbiMed Capital GP VIII LLC | 10%+ Owner | Buy | +1,195,458 | +$2.00M |
| 2026-04-08 | Charles Nolan Parker | Chief Financial Officer | A | +15,393 | — |
| 2026-03-10 | Jack E Stover | Director | A | +33,435 deriv. | — |
| 2026-03-10 | Iain D. Dukes | Chief Executive Officer | A | +231,336 deriv. | — |
| 2026-03-10 | Werner Cautreels | Director | A | +31,258 deriv. | — |
| 2026-03-10 | Nikolay Savchuk | Chief Operating Officer | A | +96,899 deriv. | — |
| 2026-03-10 | Trafford Clarke | Director | A | +33,435 deriv. | — |
| 2026-03-10 | Robert Redfield | Chief Medical Officer | A | +108,854 deriv. | — |
| 2026-03-10 | Mary Teresa Shoemaker | Director | A | +33,435 deriv. | — |
| 2026-03-10 | John Harold Leaman | Director | A | +33,435 deriv. | — |
| 2026-03-10 | Charles David Pauza | Chief Science Officer Virology | A | +118,367 deriv. | — |
| 2025-12-16 | Nikolay Savchuk | Chief Operating Officer | A | +16,419 | — |
| 2025-12-16 | Charles David Pauza | Chief Science Officer Virology | A | +18,471 | — |
| 2025-12-16 | Robert Redfield | Chief Medical Officer | A | +16,419 | — |
| 2025-12-16 | Jack E Stover | Director | A | +6,157 | — |
| 2025-12-16 | Trafford Clarke | Director | A | +6,157 | — |
| 2025-12-16 | Werner Cautreels | Director | A | +4,874 | — |
| 2025-12-16 | Iain D. Dukes | Chief Executive Officer | A | +36,943 | — |
| 2025-12-16 | Mary Teresa Shoemaker | Director | A | +6,157 | — |
| 2025-12-16 | John Harold Leaman | Director | A | +4,058 | — |
| 2025-11-25 | John Harold Leaman | Director | A | +12,770 deriv. | — |
| 2025-10-15 | Werner Cautreels | Director | A | +11,530 deriv. | — |
| 2025-10-15 | Jack E Stover | Director | A | +11,530 deriv. | — |
| 2025-10-15 | Nikolay Savchuk | Chief Operating Officer | A | +22,435 deriv. | — |
| 2025-10-15 | Charles David Pauza | Chief Science Officer Virology | A | +32,406 deriv. | — |
| 2025-10-15 | Mary Teresa Shoemaker | Director | A | +11,530 deriv. | — |
| 2025-10-15 | Iain D. Dukes | Chief Executive Officer | A | +64,839 deriv. | — |
| 2025-10-15 | Robert Redfield | Chief Medical Officer | A | +32,406 deriv. | — |
| 2025-10-15 | Trafford Clarke | Director | A | +11,530 deriv. | — |
| 2025-10-14 | John Harold Leaman | Director | A | +15,609 deriv. | — |
| 2025-06-23 | Mary Teresa Shoemaker | Director | A | +23,000 deriv. | — |
| 2025-06-23 | Werner Cautreels | Director | A | +23,000 deriv. | — |
| 2025-06-23 | Trafford Clarke | Director | A | +23,000 deriv. | — |
| 2025-06-23 | Jack E Stover | Director | A | +23,000 deriv. | — |
| 2025-04-08 | TPAV, LLC | 10%+ Owner | J | −1,211,062 | — |
| 2025-02-19 | Werner Cautreels | Chief Executive Officer | M | +96,348 | +$963 |
| 2025-01-27 | OrbiMed Capital GP VIII LLC | 10%+ Owner | Buy | +385,392 deriv. | — |
| 2025-01-27 | Nikolay Savchuk | Chief Operating Officer | Buy | +192,696 deriv. | — |
| 2025-01-27 | TPAV, LLC | 10%+ Owner | Buy | +192,696 deriv. | — |
| 2025-01-27 | Werner Cautreels | Chief Executive Officer | Buy | +192,696 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| OrbiMed Capital GP VIII LLC | 10%+ Owner | 1,203,250 | $410.43K |
| Iain D. Dukes | Chief Executive Officer | 236,934 | $80.82K |
| Nikolay Savchuk | Chief Operating Officer | 216,410 | $73.82K |
| Charles David Pauza | Chief Science Officer Virology | 115,971 | $39.56K |
| Robert Redfield | Chief Medical Officer | 113,919 | $38.86K |
| Werner Cautreels | Director | 109,222 | $37.26K |
| Charles Nolan Parker | Chief Financial Officer | 15,393 | $5.25K |
| Mary Teresa Shoemaker | Director | 6,292 | $2.15K |
| Jack E Stover | Director | 6,165 | $2.10K |
| Trafford Clarke | Director | 6,157 | $2.10K |
| John Harold Leaman | Director | 4,058 | $1.38K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TRAW quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.